Randomised Study Comparing Three Chemotherapy Regimens in Non-small Cell Lung Cancer
The purpose of this study is to determine if cisplatin-based chemotherapy, cisplatin-gemcitabine-ifosfamide or cisplatin-docetaxel, will improve survival in comparison to the combination gemcitabine-ifosfamide in patients with advanced NSCLC
Carcinoma, Non-Small-Cell Lung
DRUG: Cisplatin, Ifosfamide, Gemcitabine|DRUG: Ifosfamide, Gemcitabine|DRUG: Cisplatin, docetaxel
Survival, Survival will be dated from the first day of registration until death or last follow up
Response rate, Every 3 courses of chemotherapy|Toxicity, After each course of chemotherapy|Activity of second-line chemotherapy, Every 3 courses of chemotherapy
The purpose of this study is to determine if cisplatin-based chemotherapy, cisplatin-gemcitabine-ifosfamide or cisplatin-docetaxel, will improve survival in comparison to the combination gemcitabine-ifosfamide in patients with advanced NSCLC